Enzalutamide for treating hormone-sensitive metastatic prostate cancer: Final appraisal document

DRAFT guidance recommends enzalutamide plus androgen deprivation therapy, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults, providing company provides it according to agreed commercial arrangement.

Source:

National Institute for Health and Care Excellence